Chris Karlovich's Biography

Home
|
Register
|
Submissions
|
Agenda
|
Exhibition
|
Venue
|
Media
|
Posters
|
Short Courses
- Training Courses
|

Chris Karlovich, Associate Director, Molecular Diagnostics, Clovis Oncology, Inc.

Chris Karlovich is an Associate Director of Molecular Diagnostics at Clovis Oncology. He provides scientific and operational oversight over molecular diagnostics and companion diagnostic development for rociletinib (CO-1686), a mutant-selective inhibitor of EGFR in clinical trials for NSCLC. Prior to coming to Clovis, Dr. Karlovich spent nine years in the diagnostics industry in the areas of biomarker discovery and in vitro diagnostic (IVD) test development for companion diagnostics.

Evaluation of EGFR Mutations in Plasma from NSCLC Patients: Utility in Managing Patients on TKI Therapy

Tuesday, 28 October 2014 at 16:30

Add to Calendar ▼2014-10-28 16:30:002014-10-28 17:30:00Europe/LondonEvaluation of EGFR Mutations in Plasma from NSCLC Patients: Utility in Managing Patients on TKI TherapySELECTBIOenquiries@selectbiosciences.com

We are utilizing blood-based molecular testing in patients who have become resistant to first generation tyrosine kinase inhibitors with the goal of enabling subsequent therapy without need for repeat lung biopsy. The utility of plasma-based EGFR mutational analysis will be described in the context of CO-1686, a novel third-generation TKI that selectively inhibits the EGFR activating and T790M resistance mutations in NSCLC patients.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors